cyrilzakka/clinical-trials huggingface dataset:
Investigating the Role of the Premotor Cortex in Higher Cognitive Functions

This project aims at understanding better the role of the frontal lobe of the brain in our capacity to perceive visual information consciously, and also, in our capacity to perceive others' actions. It includes a test where we ask subjects to detect visual information in front of a computer screen, and another test where we ask them to imitate finger movements.

This project is a twofold exploration of the functions of the premotor cortex, concerning, on the one hand, its role in conscious visual perception, and on the other hand, the part it may play in the perception and imitation of other people's movements. Healthy subjects will be compared with subjects suffering from focal lesions within the premotor cortex, on two tasks: in the first task, the subjects will have to make a decision concerning the absence or presence of a visual item in their field of vision. They will make (virtual) bets based on the subjective certainty of their perceptions - they will be told that these bets are purely virtual, and will not result in any financial gain or loss. This study will help us understand the contribution of the prefrontal cortex to subjective weighing of perceptual certainty. In the second task, the subjects will imitate a finger movement, based either on a fixed picture, or on a short motion picture. Previous studies have shown that whether the movement is copied from a fixed picture or a moving picture changes reaction times and types of mistakes. Neuroimaging studies have shown that a premotor area is involved in this effect. The comparison of brain-damaged and healthy subjects will tell us what exactly the contribution of the prefrontal consists in.

Eligibility Criteria:
Inclusion Criteria:

* Healthy subjects chosen from a pool of adult subjects, recruited through ads.
* In the second group, the subjects are recruited from a pool of brain-damaged patients treated at the hospital de la Pitié-Salpétrière. They must suffer from a focal lesion in the prefrontal cortex.

Exclusion Criteria:

* For the healthy group: any previous brain-related medical history.
* Widespread brain-damage, extending beyond the prefrontal cortex, that is to say, lesions that are not really focal.
Assessment of Customized 3D Zirconium Versus Titanium Mesh for Anterior Maxillary Ridge Augmentation With Delayed Implant Placement

The aim of the present study is to assess the customized 3D zirconium versus titanium mesh for anterior maxillary ridge augmentation with delayed implant placement.


Eligibility Criteria:
Inclusion Criteria:

* Inclusion criteria:

  1. Patients from both genders with the age range of 18-60 years with good systemic health, no contraindication for periodontal surgery and able to maintain good oral hygiene.
  2. Patient with anterior maxillary alveolar ridge deficiency (horizontal, vertical or combined defects) less than 2 mm in width or less than 6 mm in height - measured from the alveolar crest to the basal bone in order to be enrolled in this study. (56)
  3. Adequate zone of keratinized gingiva at minimum 3mms.
  4. Patient with sufficient inter-arch space for future dental rehabilitation.
  5. Subjects who are not on any medication known to interfere with periodontal tissue health or healing within 6 months of the study.

Exclusion Criteria:

Exclusion Criteria:

1. History of systemic diseases (i.e. diabetes, autoimmune dysfunction, prolonged cortisone therapy, or chemotherapy) that would contraindicate periodontal surgical treatment or affect bone turn over.
2. Patients with deleterious habits like the use of tobacco chewing or smoking ones.
3. History of previous periodontal surgical treatment of the involved sites.
4. Presence of malocclusion and pathologic movement of teeth in involved sites.
5. Patient not willing to give consent for the study and poor plaque control.(57)
6. Pregnant or nursing mothers.
7. Patients with acute odontogenic infection.
Evaluation of the Marginal Integrity of Recent Bulk Fill Flowable Composite vs Glass Ionomer for Carious Cervical Restorations: RCCT

The study will be conducted to assess the marginal integrity of different types of restorations (ketac ™ N100 - ketac™ Universal and bulk fill flowable composite) in class v restoration using USPHS criteria.


Eligibility Criteria:
Inclusion Criteria:

1. Presence of at least one carious buccal cervical lesion.
2. The absence of tooth mobility.
3. Presence of contact with opposite teeth without any abnormal occlusion stress for the selected teeth.
4. Accessible isolation and observable and easily accessible gingival margins during tooth restoration.

Exclusion Criteria:

1. Patients with poor oral hygiene.
2. The presence of any para functional habit.
3. Abnormal occlusion.
4. Any regurgitation problem.
5. Subjects with compromised medical history.
6. Pulpitis, non-vital or endodontically treated teeth.
Adult Spinal Deformity Surgery Real-World Functional Activity

The purpose of this study is to measure functional activity and stability in spinal deformity patients utilizing motion analysis testing and accelerometers.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of degenerative thoracolumbar deformity
* Deformity correction surgery scheduled with either Dr. Elder or Dr. Fogelson, minimum 4-level fusion with fixation to the pelvis.

Exclusion Criteria:

° Unable to return to Mayo Clinic for follow-up evaluation
Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade

The aim of this study, comparison of effects of sugammadex versus neostigmine/atropine combination on hemodynamic parameters and intraocular pressure during tracheal extubation.

This prospective, randomised study was designed to compare two reversal methods with respect to changes in IOP, heart rate and blood pressure during tracheal extubation period.


Eligibility Criteria:
Inclusion Criteria:

* ASA I-II physical status
* elective surgery
* endotracheal intubation under general anesthesia

Exclusion Criteria:

* emergency surgery
* pregnancy
* laparoscopic surgery
* prone position
* BMI \> 30 kg/m2
* sedative drug use in last month
* patients with glaucoma.
* ASA \> II physical status
Treatment Adherence and Outcomes in Three Modalities of Continuous Positive Airway Pressure Treatment for Obstructive Sleep Apnea

The purpose of this study is to compare the treatment adherence and effects in three modalities of Continuous Positive Airway Pressure Treatment for Obstructive Sleep Apnea.

Obstructive sleep apnea (OSA) is a common disorder that is associated with substantial morbidity, including excessive daytime sleepiness, hypertension, and cardiovascular disease. Although Continuous Pressure Airway Pressure (CPAP) is effective treatment of objective and subjective complaints, adherence to CPAP therapy is suboptimal. Recently, pressure-relief CPAP (C-flex,A-flex; Respironics; Murrysville, PA) is available. The present study is single-blind,prospective, randomised, crossover study to compare the adherence and effects of therapy with C-flex, A-flex, and autoadjusting CPAP after 3 months of CPAP treatment.

Additionally, after 3 months of CPAP treatment, the patients who treated with C-flex and A-flex will crossovered, we will acess to change of adherence and effects of CPAP treatment.

Eligibility Criteria:
Inclusion Criteria:

* Subjects on admission for sleep study under the Respiratory Care and Sleep Control Medicine, Kyoto University Hospital.
* Subjects diagnosed with OSA (apnea hypopnea index \>=5/hour) by overnight polysomnography.

Exclusion Criteria:

* Subjects diagnosed with CSA by overnight polysomnography.
* Subjects ever used CPAP for OSA.
Liposomal Bupivacaine in Ambulatory Hand Surgery

This study is being done to evaluate pain management regimens following ambulatory hand surgery. Improved pain control may be associated with decreased complications, decreased pain scores, decreased opioid dependence, improved patient comfort and satisfaction, and reduced healthcare costs. Liposomal bupivacaine is an FDA-approved local anesthetic. There will be two groups. One group will receive liposomal bupivacaine. One group will not. The results will be compared.

Patients will be over the age of 18 ambulatory hand surgery. Approximately 40 subjects will participate in this study at LLU.


Eligibility Criteria:
Inclusion Criteria:

* Patients 18 years of age and over undergoing ambulatory hand surgery involving soft tissue and subfascial structures, including: CMC arthritis, flexor and extensor tendon injury, symptomatic ganglia, hand and finger fractures

Exclusion Criteria:

* Patients who are unable to give informed consent to participate in this study
* Patients with a documented history of hypersensitivity reactions to local anesthetic agents
* Patients with a diagnosis of chronic pain disorders such as fibromyalgia, chronic migraine headaches, or psychiatric disorders other than depression or anxiety
* Patients who are currently pregnant
* Patients with impaired hepatic function
* Patients with underlying nerve damage or impairment
* Patients with renal impairment/failure
* Patients whose career/livelihood require a great deal of hand dexterity, in whom a complication could cause a significant impact on life and career (ex: musician, dentist)
Neurectomy Vs Nerve Sparing in Open Inguinal Hernia Repair

It is a randomized controlled trial in which we are treating inguinal hernia patients with mesh hernioplasty and either neurectomy of iliohypogastric nerve and ilioinguinal neurectomy or preservation comparing post operative acute or chronic pain


Eligibility Criteria:
Inclusion Criteria:

* patients male, and age between 20 to 70 years Reducible inguinal hernia

Exclusion Criteria:

* Irreducible, obstructed or strangulated hernia uncontrolled diabetes
Evaluate the Impact of Targeted Physical Activity on Clinically Debilitated Dialysis Patients.

This research is being done to better understand the impact of the use of a specific physical activity training program (GH Method) in dialysis/kidney disease patients.

The 12-Month Randomized Trial Group will include a total of 150 patients from UI Health (≥ 18 years of age), who are on dialysis, or have chronic kidney disease stage 4 (CKD 4 = GFR between 15 and 29) or have chronic kidney disease stage 5 (CKD 5 = GFR below 15) and are considered clinically debilitated by their direct healthcare professional will be enrolled. Randomization will be a 2:1 ratio (100 intervention, 50 control). The intervention arm will perform a 12-month exercise intervention which involves two days a week of personalized exercise rehabilitation. The control arm will receive no exercise intervention. Both arms of patients will be tested on various measures of health and function both at baseline (prior to intervention) at 6 months, and at 12 months (post intervention). This study will also investigate the effects of an exercise intervention on a subgroup of pre- and post- kidney transplant patients (PPKT Subgroup). This subgroup will include a total of 100 patients (≥ 18 years of age), who are on dialysis, or have CKD stage 4 or 5, and are considered clinically debilitated by their direct healthcare professional will be enrolled, or post- renal (kidney) transplant. This subgroup will perform 36 visits of exercise intervention which involves two days a week of personalized exercise rehabilitation. The Investigator will also utilize validated surveys and assessment tools to assess health issue management and depression severity.

Eligibility Criteria:
Inclusion Criteria:

* Clinically debilitated patients, currently on dialysis, or have CKD 4 (GFR between 15 and 29), or have CKD 5 (GFR below 15), or post- kidney transplant (for PPKT Subgroup only) as stated by patient's health care professional.
* Adequate cognitive ability to complete the questionnaires, give consent for the study and follow the physical and diet instructions

Exclusion Criteria:

* cardiac/pulmonary disease that contraindicate the physical training
* Unable to give consent
* Unable to travel to the training center
Novel Skin Care for Immunotherapy- Related Dermatologic Toxicities

Notwithstanding the continuous progress in cancer treatment, patients with cancer still have to cope with quality of life (QoL) - impairing complications. Especially an extensive spectrum of dermatologic toxicities has been associated with cancer treatments. The number and type of cutaneous toxicities have evolved over the past 50 years, paralleling the development of new immunomodulatory agents. The immunotherapy-related skin toxicities can significantly impede the patient's emotional, physical, social, and financial well-being resulting in a poor QoL. In rare cases of severe cutaneous reactions, treatment modifications are needed, resulting in a diminished overall survival.

Important organizations in the field of oncology and supportive care, such as the MASCC, the ASCO, and the ESMO, have developed guidelines for the management of cancer therapy- related cutaneous toxicities based on available scientific evidence. Still, for some interventions, the evidence of recommendation is moderate to insufficient. Therefore, it is essential to elucidate other new potential management strategies for dermatological complications of cancer treatment. Based on the previously mentioned supportive care guidelines for the ImmunoSkin project, two novel skin care products to tackle the cutaneous adverse events of immunotherapy have been developed.

The ImmunoSkin project general aim is to evaluate the efficacy of two novel skincare products to manage immunotherapy-related cutaneous toxicities.

Primary objective Evaluate the efficacy of two novel skin care products for the management of immunotherapy-related cutaneous adverse events

Secondary objective 1 Evaluate patient-relevant treatment benefit of two novel skin care products for immunotherapy-related cutaneous toxicities

Secondary objective 2 Evaluate the influence of two novel skin care products for immunotherapy-related cutaneous toxicities on the patient's quality of life

Secondary objective 3 Evaluate the safety of two novel skin care products for immunotherapy-related cutaneous toxicities

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with cancer of any type
* Undergoing immunotherapy, check point inhibitors, at the Jessa Hospital (Hasselt, BE)
* Age ≥ 18 years
* Able to comply to the study protocol
* Able to sign written informed consent

Exclusion Criteria:

* Pre-existing skin rash, ulceration, skin infections or open wounds
* Severe psychological disorder or dementia
* Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator
Safety Study of Use of Hyaluronic Acid Gel To Prevent Intrauterine Adhesions In Hysteroscopic Surgery

Operations in the uterus are currently possible using a hysteroscope. One serious though rare complication of such procedures is the development of intra-uterine adhesions. There currently are no methods to prevent this. The aim of this study is to evaluate the safety of using hyaluronic gel after hysteroscopic surgery.

Operations in the uterus are currently possible using a hysteroscopic approach. Intrauterine procedures include; polypectomy, myomectomy, removal of lost IUD,removal of a septum and more. One serious though rare complication of operative hysteroscopy is the development of intra-uterine adhesions. Such adhesions, also known as asherman's syndrome, can cause serious consequences such as infertility and miscarriage. The hypothesis is that the removal of the endometrium and the exposure of ra uterine wall to each other can cause attachment and adhesions. the treatment is to mechanically break the adhesion. recurrence is however common. There currently are no methods to prevent adhesions following curettage or hysteroscopy. The aim of this study is to evaluate the safety of using hyaluronic gel after hysteroscopic surgery. At a later research, the efficacy of barrier gel will be measures.

Eligibility Criteria:
Inclusion Criteria:

* age 18 year old and over
* need of hysteroscopic surgery

Exclusion Criteria:

* preoperative fever or infection
* malignancy
* previous PID
* contraindications for anesthesia
* pregnancy
* under 18 year old
* not able to read and/or understand informed consent
* taking any medicine other than oral contraceptives
Optimized Medico-pharmaceutical Collaboration in the Drug Management of Patients With Heart Failure

This is a controlled, randomized, open-label, multicentric study evaluating the value of coordinated medico-pharmaceutical management compared to standard management in patients with heart failure. The aim of this study is to evaluate the impact of these optimized activities on the re-hospitalization of the patient with cardiac insufficiency for a disease-related event within three months of the initial hospitalization.

Heart failure (FH) is a public health problem with an estimated prevalence of about 1.5% in developed countries. In 2013, the number of patients hospitalized in France for heart failure amounted to 165 231 and 20% of them were re-hospitalized at least once for the same reason during this year. Several factors contribute to the occurrence of cardiac decompensation (DC) : some modifiable (age, severity of IC, etiology ...) and others modifiable, such as therapeutics. Various elements could reduce the frequency of re-hospitalizations and the mortality due to this disease :

* a better knowledge of treatments by patients and consequently a better therapeutic compliance
* a better knowledge of the factors and signs of DC (low-sodium diet, weighing...)
* a better implementation of prescribing recommendations : less than 50% of patients have optimal treatment compared to ESC recommendations
* a better communication at the transition points of the patient pathway. The creation of a binomial cardiologist-clinical pharmacist during hospitalization and the maintenance of this optimized multidisciplinary follow-up within 3 months post-hospitalization is a proposal to intervene on these factors. Indeed, the clinical pharmacist (present in the care unit) works in collaboration with the medical and paramedical teams and can improve the care of patients. In the experimental group, a specific multidisciplinary consultation is planned for one month after the end of the hospitalization. A 3-month follow-up visit will be carried out by phone call to meet the criteria for readmission, mortality, quality of life, adherence and persistence of treatments.

Eligibility Criteria:
Inclusion Criteria:

* Patient aged more than 18 years
* Adult patient admitted in cardiology department (full hospitalisation or intensive care) for heart failure no matter the type and the stage of the disease
* Person affiliated or beneficiary of a social security system
* Collection of a free, informed, express and written consent

Exclusion Criteria:

* Non autonomous drug management patients and not disposing
* a present caregiver during hospitalisation
* Patients living in an institution
* Person participating in another clinical trial with an exclusion period still ongoing
* Person whose physical and/or psychological health is severely altered, and which, in the opinion of the investigator, may affect the participation's to the study
* Person deprived of his rights, person under tutorship or guardianship
* Refusal to sign the consent
Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma

Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.

Glioblastomas are the most frequent and aggressive malignant Central Nervous System (CNS) tumors in adults, with a median survival of only 14 months.

Current treatment is based on surgery followed by radiochemotherapy (STUPP protocol), unchanged since 2005. Clinical trials evaluating immune checkpoint inhibitors and targeted therapies have largely failed to demonstrate efficacy in these tumors. In order to better understand the oncogenesis of glioblastoma and identify potential new therapeutic targets, the study of the characteristics of relapsed tumors compared with the initial tumor seems relevant.

The aim of this retrospective study is to investigate the transcriptomic, proteomic and metabolic characteristics of relapsed glioblastomas reoperated at the University Hospital of Bordeaux, France, between 2005 and 2023, for which tumor material is available. These analyses will be correlated with relapse-free and overall survival of the patients.

Eligibility Criteria:
Inclusion Criteria:

* age \> 18 years
* surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux

Exclusion Criteria:

* systemic therapy received for non-glioblastoma tumor
Blood Fibrocytes During an Exacerbation and Lung Function Decline in Patients With COPD in Primary Care.

This study aims to estimate the association between blood fibrocytes measured during a suspected exacerbation and 3-year decline forced expiratory volume in one second (FEV1), in patients with Chronic obstructive pulmonary disease (COPD) in primary care, with a history of smoking, independently of the number of exacerbations and of tobacco or occupational exposure.

COPD is highly prevalent in primary care. It is associated with tobacco smoke or toxic occupational exposure. Some COPD patients will experience a faster decline in quality of life and lung function. There is currently no prognostic marker allowing to identify those patients at higher risk of fast lung function decline. Recent data suggest that fibrocytes are involved in COPD's physiopathology. A higher blood fibrocytes level during an acute exacerbation has been associated with higher mortality in COPD patients at a late stage of the disease. In mice, fibrocytes role in lung function decline has been demonstrated at an early stage. To date, association between blood fibrocytes during an exacerbation and lung function decline has not been evaluated at the early stage of COPD in humans.

This study aims to estimate the association between blood fibrocytes measured during a suspected exacerbation and 3-year decline in forced expiratory volume in one second (FEV1), in patients with COPD in primary care, with a history of smoking, independently of the number of exacerbations and of tobacco or occupational exposure.

In this study, blood fibrocytes during a suspected exacerbation will be measured at inclusion. The lung function (FEV1) will be assessed at follow-up visits at 2 months, 12 months and 36 months after inclusion. COPD-related health status and severity of dyspnea will be assessed with COPD Assessment test (CAT) and the modified Medical Research Council dyspnea scale (mMRC) at follow-up visits at 2 months, 12 months and 36 months after inclusion.

Eligibility Criteria:
Inclusion Criteria:

* man or woman aged more than 40 years old,
* with tobacco exposure of more than 20 pack-years,
* Presenting to a General Practitioner with a suspected mild or moderate COPD exacerbation according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (worsening of symptoms with the need for prescribing short acting bronchodilatators, antibiotics or oral corticosteroids)
* Informed consent given
* Affiliated to a social insurance scheme

Exclusion Criteria:

* Severe exacerbation of COPD according to GOLD guidelines (patient requires hospitalization or visits to the emergency room),
* More likely differential diagnosis than a COPD exacerbation, such as pneumonia, acute pulmonary oedema or other differential diagnosis,
* history of asthma, pulmonary fibrosis, primary pulmonary hypertension or chronic viral infections (HIV, hepatitis)
* person under care or protection of vulnerable adults